New drug aims to tame phosphate levels in kidney patients on dialysis

NCT ID NCT06712654

Recruiting now Disease control Sponsor: R1 Therapeutics Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated Jun 14, 2026 · Updated 5 times

Summary

This study tests a new medicine called AP306 to see if it can safely lower high phosphate levels in adults with kidney failure who are on hemodialysis. About 168 participants will receive either AP306 or a placebo. The goal is to control phosphate, a common problem in dialysis patients, not to cure kidney disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE REQUIRING CHRONIC DIALYSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Academic Medical Research Institute
RECRUITING

Los Angeles, California, 90022, United States
Apogee Clinical Research, LLC
NOT_YET_RECRUITING

Huntsville, Alabama, 35801, United States
California Institute of Renal Research
NOT_YET_RECRUITING

Chula Vista, California, 91910, United States
Colorado Kidney Care
RECRUITING

Denver, Colorado, 80220, United States
DaVita Clinical Research
RECRUITING

Middlebury, Connecticut, 06762, United States
DaVita Clinical Research
RECRUITING

Las Vegas, Nevada, 89107, United States
DaVita Clinical Research
RECRUITING

Houston, Texas, 77054, United States
DaVita Clinical Research
NOT_YET_RECRUITING

San Antonio, Texas, 78258, United States
DaVita Clinical Research
NOT_YET_RECRUITING

Norfolk, Virginia, 23502, United States
Gamma Medical Research
NOT_YET_RECRUITING

McAllen, Texas, 78503, United States
Johnson County Clinical Trials
RECRUITING

Kansas City, Missouri, 64111, United States
Peking University First Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100035, China
Peking University People's Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100044, China
Renal Medicines Associates
NOT_YET_RECRUITING

Albuquerque, New Mexico, 87109, United States
Shanghai Jiao Tong University School of Medicine, Renji Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 201112, China
Sichuan Provincial People's Hospital
NOT_YET_RECRUITING

Chengdu, Sichuan, 610072, China
St. Clair Nephrology Research
RECRUITING

Shelby, Michigan, 48315, United States
Sunbeam Research
RECRUITING

Greenville, Texas, 75402, United States
The Second Affiliated Hospital of Nanjing Medical University
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210003, China
US Renal Care
NOT_YET_RECRUITING

Orange, Connecticut, 06477, United States
US Renal Care
NOT_YET_RECRUITING

Fort Myers, Florida, 33912, United States
US Renal Care
NOT_YET_RECRUITING

Dalton, Georgia, 30720, United States
US Renal Care
NOT_YET_RECRUITING

Toledo, Ohio, 43613, United States
US Renal Care
NOT_YET_RECRUITING

San Antonio, Texas, 78251, United States
Zhengzhou University-First Affiliated Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, 450003, China
Zhongda Hospital Southeast University
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210009, China

Conditions

The condition(s) this trial relates to.

end stage renal failure hyperphosphatemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE REQUIRING CHRONIC DIALYSIS END STAGE RENAL DISEASE ON DIALYSIS HYPERPHOSPHATEMIA